Teva Sues Perrigo Over Proair Asthma Inhaler Patents
BRIEF: Teva Sues Perrigo Over Proair Asthma Inhaler Patents [Globes, Tel Aviv, Israel]
From Globes (Tel Aviv) (September 9, 2012)
Sept. 09--Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) unit Teva Branded Pharmaceutical Products R&D Inc. has filed patent infringement suit with the US District Court for the District of Delaware against Perrigo Company (Nasdaq:PRGO; TASE:PRGO) and Catalent Pharma Solutions Inc. over their joint generic version of the generic version of ProAir HFA aerosol inhaler. Perrigo and Catelent partner filed an Abbreviated New Drug Application (ANDA) with the US Food and Drug Administration (FDA) for the asthma treatment on Friday.
Perrigo cites data by Wolters Kluwer Health that brand ProAir has $1.07 billion in annual sales.
According to Teva, its ProAir patents expire in 2017 and 2023, and contends in its statement of claim that it would be "irreparably harmed" by the generic versions of the inhaler.
Perrigo chairman and CEO Joseph Papa said, "This filing is another example of our long-term investment in extended topical (respiratory) product development. We are pleased to be partnering with Catalent on this important new product opportunity."
(c)2012 the Globes (Tel Aviv, Israel)
Visit the Globes (Tel Aviv, Israel) at www.globes.co.il/serveen/globes/nodeview.asp?fid=942
Distributed by MCT Information Services
Posted: September 2012